Showing results (421-430 of 654) with videos related to

Sort By:
Pageof 66
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 23, 2023
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II TrialFunda Meric-Bernstam, Vicky Makker, Ana Oaknin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 25, 2024
Antitumor Activity and Biomarker Analysis for TROP2 Antibody-Drug Conjugate Datopotamab Deruxtecan in Patient-Derived Breast Cancer Xenograft ModelsFunda Meric-Bernstam, Erkan Yuca, Kurt W Evans, et al.
Gynecologic Oncology|January 9, 2025
A phase I study of temsirolimus in combination with metformin in patients with advanced or recurrent endometrial cancerJibran Ahmed, Bettzy Stephen, Muhammad R Khawaja, et al.
Cancer Chemotherapy and Pharmacology|June 14, 2023
A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutationSarina A Piha-Paul, Chieh Tseng, Hai T Tran, et al.
Journal for Immunotherapy of Cancer|April 22, 2017
Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignanciesMatthew J Reilley, Ann Bailey, Vivek Subbiah, et al.
Molecular Cancer Therapeutics|March 31, 2019
Prospective Clinical Sequencing of Adult GliomaSiyuan Zheng, Kristin Alfaro-Munoz, Wei Wei, et al.
The Oncologist|December 13, 2025
Phase I Study of Bevacizumab and Temsirolimus Combination Therapy in Advanced Malignancies: Safety, Efficacy, and Ovarian Cancer ExpansionSarina A Piha-Paul, Chieh Tseng, Emily Thompson, et al.
NPJ Precision Oncology|January 13, 2026
Therapeutic responses in patients with advanced NSCLC enrolled in early-phase clinical trials at MD AndersonJeong Uk Lim, Heather Y Lin, Lei Kang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2019
Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic CancerSeyed Pairawan, Kenneth R Hess, Filip Janku, et al.
JCO Precision Oncology|September 11, 2020
Efficacy of Vemurafenib in Patients With Non-Small-Cell Lung Cancer With BRAF V600 Mutation: An Open-Label, Single-Arm Cohort of the Histology-Independent VE-BASKET StudyVivek Subbiah, Radj Gervais, Gregory Riely, et al.
Pageof 66